Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. COVID-19 generated by SARS-CoV-2 infection may cause mild, moderate, or severe illness; the latter includes severe pneumonia, ARF, ARDS, AKI, endothelial damage, coagulopathy, sepsis and septic shock.
As in sepsis, endotoxemia can be found in the blood of patients with COVID-19 pneumonia, indicating that loss of intestinal barrier function significantly contributes to the pathogenesis of COVID-19.
Patients who are hospitalized for extended periods in an ICU are more prone to superimposed infections.
Gram-negative infection and/or direct mucosal gut translocation lead to the circulation of endotoxin (endotoxemia).
During this webinar we discuss the pathophysiology of septic shock and COVID-19, the role of endotoxemia and rationale of Polymyxin B hemoperfusion in specific populations.
Data on Polymyxin B hemoperfusion use in Endotoxic Shock patients will be presented including COVID-19 patients, discussing the complementary role of EUPHAS 2 registry in addition to RCT studies.
Finally, we will talk about sepsis-induced AKI, the importance of dialysis membrane as therapeutic choice and the new approach of sequential therapies in sepsis treatment.
Start Promotion Eventi S.r.l.
Via Mauro Macchi, 50
20124 Milano - Italy
Tel. +39 02 67071383
Fax +39 02 67072294
Please refer to: